Lead, GRD

Real World Evidence Lead, HIDO, Global Rare Diseases

Date: 23 Jul 2026

Department: GRD Global Medical Affairs

Business Area:
Mktg, Market Access, Bus. Excellence & Med. Affair

Job Type: Direct Employee

Contract Type:
Permanent

Location:

United States, US

Chiesi is an international research‑focused biopharmaceutical group with 90 years’ experience, operating in more than 30 countries, with its Headquarter in Parma, Italy. More than 8,000 employees across the group are united by a singular purpose: promoting a healthier world for our people, patients, and the planet. This is what drives us as we research, develop, and market innovative drugs across our main therapeutic areas.

Discover more here.

At Chiesi we are thinking generations ahead, driving sustainable innovation with purpose. This fosters a culture of reliability, transparency, and ethical behaviour at every level. As a Benefit Corporation and a certified B Corp, we have embedded sustainability in our bylaws and continuously measure our impact.

Diversity and inclusion are at the heart of who we are. We believe our differences make us stronger. We are a vibrant ecosystem of passionate, talented individuals united by strong values, each bringing unique perspectives that help us to continuously challenge the status quo for the better.

Chiesi Global Rare Diseases is a Chiesi Group’s business unit established in February 2020 and focused on research, development and commercialization of treatments and patient support services for rare and ultra‑rare disorders, many of whom have limited or no treatments available.

This unit is based in Boston, Massachusetts, with a strong synergy with the headquarters in Parma.

Rare unit has a focus on research and product development for lysosomal storage diseases, rare hematology, ophthalmology disorders and rare immunodeficiencies. The unit is also a dedicated partner with global leaders in scientific research, patient advocacy and care. Discover more here.

Reporting to the Sr. Director, RWE, Global Rare Diseases, the Real World Evidence Lead HIDO is responsible for leading and executing the global RWE strategy and vision for the Hematology, Immunology, Dermatology and Ophthalmology (HIDO) Portfolio within GRD, ensuring the strategy, creation and updating of the integrated evidence generation plan (IEGP), in alignment with cross‑functional partners to meet research and commercial objectives.

This role drives enterprise‑level RWE impact, including building strategic data partnerships, advancing innovative methodologies, and influencing cross‑functional decision‑making.

Act as a change agent, effectively communicating the value of RWE and influencing adoption of new processes and approaches. This includes:

• Lead the global RWE strategy for the HIDO GRD portfolio, acting as the strategic RWE leader across development, regulatory, and commercialization phases, and ensuring its integration into regulatory, payer, and clinical decision‑making across the HIDO Portfolio including Ferriprox® (deferiprone) in Iron overload (e.g., beta‑thalassemia, SCD), Filsuvez® (birch triterpenes) Epidermolysis bullosa, Raxone® (idebenone) Leber’s Hereditary Optic Neuropathy and future pipeline or acquired assets.
• Increase the integration of RWD sources to enhance evidence‑based decision making through research programs, while providing medical leadership as appropriate on cross‑functional teams supporting local and global needs in a prioritized manner.
• Publish, where appropriate in high impact journals.

• Continuously improve RWE capabilities, processes, and infrastructure to support global and local evidence generation for HIDO Build and scale RWE capabilities as a competitive advantage for GRD
• Establish best practices, standards, and ways of working across regions
• Lead change management to embed RWE into core organizational processes

• Lead identification, evaluation, and execution of external RWD partnerships and data acquisition strategies
• Oversee due…